Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care
Cost: FreeView Offer chevron_right
Topics covered in Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care include:
Epidemiology, clinical features, presentation, pathophysiology, and disease progression, patient population identification among healthcare professionals of different specialties, diagnostic tests, genetic testing and patient cases.
After completing Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care, you will be able to:
• Describe the pathophysiology of AATD and how it impacts treatment of the disorder
• Assess the clinical significance of AATD laboratory results and apply them to patient cases
• Describe the clinical presentation of patients with A1ATD and, given a patient case, formulate a treatment plan
• Recall barriers to care for AATD and its clinical management in current practice
Pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.